Sobi acquires full rights to rheumatoid arthritis drug from Amgen
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum (Sobi) has acquired full rights to develop and commercialize Kineret (anakinra) from Amgen for all therapeutic indications. Previously, Sobi had Kineret rights for rheumatoid arthritis and four orphan drug indications, including Cryopyrin Associated Periodic Syndrome (CAPS).